Literature DB >> 28122676

Prognostic impact of nodal statuses in patients with pancreatic ductal adenocarcinoma.

Yasunari Fukuda1, Tadafumi Asaoka2, Sakae Maeda3, Naoki Hama3, Atsushi Miyamoto3, Masaki Mori2, Yuichiro Doki2, Shoji Nakamori4.   

Abstract

BACKGROUND: The present study aimed to clarify the prognostic impact of nodal statuses in pancreatic ductal adenocarcinoma (PDAC) after potentially curative pancreatectomy.
METHODS: In 110 patients with >10 examined lymph nodes (ELNs), we investigated how nodal statuses were associated with postoperative survival. Nodal statuses included the number of positive LNs (PLNs); the ratio of PLNs to ELNs (lymph node ratio; LNR); and the location of regional LN metastases, classified as group one (peripancreatic area) and group 2 (outside the peripancreatic area). The maximum χ2 value, provided by a Cox proportional hazards model, was used to determine the optimal cutoff value for the number of PLNs and the LNR.
RESULTS: The median numbers of ELNs and metastatic LNs were 33 and 2, respectively. Median survival was longer in patients with ≤3 PLNs (37.5 months), LNR <0.11 (36.1 months), and group 1 LN metastases (37.5 months) compared to in patients with ≥4 PLNs (23.7 months), LNR ≥0.11 (23.9 months), and group 2 LN metastases (22.8 months), respectively. Multivariate analyses revealed that all three investigated nodal statuses were independent factors associated with survival: HR of 2.38 and p = 0.0006 for the location of LN metastases, HR of 1.92 and p = 0.0071 for the number of PLNs, and HR of 1.89 and p = 0.010 for the LNR.
CONCLUSIONS: Three nodal statuses-the number of PLNs, the LNR, and the location of LN metastases-could stratify postoperative survival among PDAC patients with an adequate number of examined LNs after pancreatectomy.
Copyright © 2017 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Lymph node; Pancreatic ductal carcinoma; Survival analysis

Mesh:

Year:  2017        PMID: 28122676     DOI: 10.1016/j.pan.2017.01.003

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  5 in total

1.  KRAS mutant-driven SUMOylation controls extracellular vesicle transmission to trigger lymphangiogenesis in pancreatic cancer.

Authors:  Yuming Luo; Zhihua Li; Yao Kong; Wang He; Hanhao Zheng; Mingjie An; Yan Lin; Dingwen Zhang; Jiabin Yang; Yue Zhao; Changhao Chen; Rufu Chen
Journal:  J Clin Invest       Date:  2022-07-15       Impact factor: 19.456

Review 2.  Emerging Role for 7T MRI and Metabolic Imaging for Pancreatic and Liver Cancer.

Authors:  Debra Rivera
Journal:  Metabolites       Date:  2022-04-30

3.  Rethinking the TNM Classification Regarding Direct Lymph Node Invasion in Pancreatic Ductal Adenocarcinoma.

Authors:  Fiona Speichinger; Mihnea P Dragomir; Simon Schallenberg; Florian N Loch; Claudius E Degro; Ann-Kathrin Baukloh; Lisa Hartmann; Ioannis Pozios; Christian Schineis; Georgios Antonios Margonis; Johannes C Lauscher; Katharina Beyer; Carsten Kamphues
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

4.  Lymph node ratio is a superior predictor in surgically treated early-onset pancreatic cancer.

Authors:  Yangyang Zheng; Zhenhua Lu; Xiaolei Shi; Tianhua Tan; Cheng Xing; Jingyong Xu; Hongyuan Cui; Jinghai Song
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

5.  Prognostic impact of lymph node status in patients after total pancreatectomy for pancreatic ductal adenocarcinoma: A strobe-compliant study.

Authors:  Zhen-Jiang Zheng; Mo-Jin Wang; Chun-Lu Tan; Yong-Hua Chen; Jie Ping; Xu-Bao Liu
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.